Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 24 hour
7-point ordinal scale
absence
addition
administration
Admission
ALT
anticipated
assigned
AST
baseline
biological parameters
candidate
Care
clinical
Clinical research
clinical status
clinical trial
clinician
Comorbidity
conditions
Control
control arm
control group
Coronavirus infections
Council
COVID 19
COVID-19
COVID-19 infection
criteria
current
D-dimer
Day
death rate
decrease
discharge
dissemination
dose
drug
Duration
early stage
Efficacy
element
ELISA
enrolment
EudraCT
European
evaluate
exclusion criteria
exploratory
extracorporeal membrane oxygenation
Frame
harmonization
hospitalisation
hospitalised
hospitalised patient
hyperinflammatory status
hypersensitivity
Hypothesis
identify
IL-6
IL-6 levels
IL-6 receptor inhibitors
IL-6R
In-hospital
incidence
Inclusion
inclusion criteria
independent
Infection
Informed
inhibitor
interstitial pneumonia
Intervention
intervention group
intestinal perforation
Invasive mechanical ventilation
investigator
investigator-initiated
lactation
Local
marker
measure
mechanical ventilation
moderate
moderate-severe
neutrophil count
Non-invasive
non-invasive ventilation
number
number of death
objective
Open label trial
outbreak
outcome
oxygen
Oxygenation
pandemic
participant
pathogen
patients treated
performed
Platelet
Pneumonia
positive
positive RT-PCR
Positive test
Prednisone
Presence
Prevent
progression
protocol
random
randomisation
randomised
randomised controlled trial
receive
recruited
recruitment
Registered
reported
requiring supplemental oxygen
responsible
routine clinical practice
RT-PCR
SAEs
Sample size
sarilumab
SARS-CoV-2
SARS-COV-2 infection
score
Sepsis
Serious Adverse Event
serum
Severe COVID-19 Infection
single center
single dose
Spain
Standard
Standard of care
status
Study protocol
Subcutaneous
subcutaneous injection
the patient
therapy
treated
Treatment
treatment arm
treatment with tocilizumab
Trial
ULN
union
unit
verbal
website
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter